Overview
Medigene AG is a biotechnology firm based in Germany, primarily engaged in the development of immunotherapies for the treatment of cancer. The company leverages cutting-edge research to advance its expertise in T cell-receptor (TCR) therapies, aiming to develop treatments that can specifically target and combat tumorous cells in a highly effective manner. Key projects include TCR-based therapies in clinical trials, designed to enhance the immune system's ability to recognize and destroy cancer cells with high precision. Medigene’s strategic focus is not only on the development but also on the commercialization of its therapies, looking to fill critical gaps in available cancer treatments and improve patient outcomes in the oncology sector.
AI+ Ask Fintel’s AI assistant about Medigene AG.
Thinking about good questions…
Basic Stats
The Factor Analysis chart (below right) shows a view of Medigene AG from a variety of lenses. Each factor shows how well the company ranks against all other companies in the Fintel global investing universe. Factor scores range from zero to 100, with 100 being most desirable, and 50 being average.
For example, a company with a Value Score of 100 would be the most undervalued company in our database. A company with a Value Score of zero would be the most overvalued.
| Market Cap | |
| EV | |
| Shares Out. | 0.00 MM |
| Earnings Date | |
| EPS (TTM) | |
| Dividend Yield | |
| Ex-Dividend Date | |
| Borrow Rate | |
| Short Shares Avail. | |
| Short Interest | |
| Short Float | |
| Days to Cover | |
| Risk Free Rate | 4.17 % |
| Price Change (1 yr) | |
| Volatility (1 yr) | |
| Beta | |
| Sharpe Ratio (1 yr) | |
| Sortino Ratio (1 yr) |
| PE Ratio | |
| Price/Book | |
| Price/TBV | |
| Book/Market | |
| EBIT/EV | |
| EBIT(3yr avg)/EV | |
| ROA | 0.00 |
| ROE | 0.00 |
| ROIC | |
| CROIC | |
| OCROIC | |
| Implied Volatility | |
| Put/Call OI Ratio |
| Growth | |
| Profitability | |
| Quality Score | |
| Value Score | |
| Momentum Score | |
| Stability (Low Vol) Score | |
| Analyst Sentiment | |
| Fund Sentiment | |
| Insider Sentiment | |
| Officer Sentiment | |
| Dividend Score | |
| QVM Score | |
| Piotroski F-SCORE | 1.00 /9 |
Factor Scores range from 0 to 100, with 100 being most desirable. Larger circles are better. In situations where we have no data (e.g. no insider trades), we plot the score at 50 to avoid penalizing companies. However, a company that does not pay dividends will get a Dividend Score of Zero. Additionally, we inverted volatility to create a "stability" metric which is better when higher.
Price Target
The average one-year price target for Medigene AG is € 3,69. The forecasts range from a low of € 3,65 to a high of € 3,80. A stock’s price target is the price at which analysts consider it fairly valued with respect to its projected earnings and historical earnings. Analysts typically set price targets that correspond to their buy or sell recommendations.
Update Frequency: Monthly
Stock Upgrades/Downgrades
This card shows analyst upgrades/downgrades for Medigene AG. An analyst rating is a classification that gives investors a sense of analyst sentiment about the direction and performance of an equity - usually a stock - over a period of time, typically 12 months.
The standard analyst ratings are generally as follows:
- Buy/Overweight/Outperform - Any of these ratings conveys an analyst’s belief that the stock is likely to outperform a market index (e.g. the S&P 500).
- Hold/Equal-Weight/Market Perform - Any of these ratings conveys an analyst’s belief that the stock is likely to perform in line with a market index.
- Sell/Underweight/Underperform - Any of these ratings suggest that an analyst believes the stock is likely to underperform a market index.
When an analyst upgrades a stock, they are signaling that the company’s fundamentals are being undervalued by investors. It could also mean they believe the market is underestimating the company’s potential. The opposite is true when a stock receives a downgrade.
The average rating of each individual analyst’s rating is the consensus rating for a stock. This gives investors a broader sense of the overall sentiment for that stock.
| Date | Analyst | Prior | Latest Recommendation |
Action |
|---|---|---|---|---|
| 2024-06-19 | H.C. WAINWRIGHT & CO., LLC | Buy | Buy | Maintains |
| 2024-03-27 | BAADER HELVEA EQUITY RESEARCH | Buy | Buy | Maintains |
| 2023-11-22 | H.C. WAINWRIGHT & CO., LLC | Buy | Buy | Maintains |
| 2023-11-21 | H.C. WAINWRIGHT & CO., LLC | Buy | Buy | Maintains |
| 2023-10-26 | BAADER HELVEA EQUITY RESEARCH | Buy | Buy | Maintains |
| 2023-10-25 | BAADER HELVEA EQUITY RESEARCH | Buy | Buy | Maintains |
| 2023-08-17 | H.C. WAINWRIGHT & CO., LLC | Buy | Buy | Maintains |
| 2023-08-16 | H.C. WAINWRIGHT & CO., LLC | Buy | Buy | Maintains |
| 2023-06-01 | H.C. WAINWRIGHT & CO., LLC | Buy | Buy | Maintains |
| 2023-05-31 | H.C. WAINWRIGHT & CO., LLC | Buy | Buy | Maintains |
| 2022-08-04 | BERENBERG | Buy | Buy | Maintains |
| 2022-08-03 | BERENBERG | Buy | Buy | Maintains |
| 2022-03-23 | STIFEL EUROPE | Buy | Buy | Maintains |
| 2022-03-22 | STIFEL EUROPE | Buy | Buy | Maintains |
| 2022-02-23 | EQUI.TS | Neutral | Neutral | Maintains |
| 2022-02-22 | EQUI.TS | Neutral | Neutral | Maintains |
| 2021-04-01 | EQUI.TS | Neutral | Neutral | Maintains |
| 2021-03-31 | EQUI.TS | Neutral | Neutral | Maintains |
| 2021-03-25 | BAADER HELVEA EQUITY RESEARCH | Buy | Buy | Maintains |
| 2021-03-24 | BAADER HELVEA EQUITY RESEARCH | Buy | Buy | Maintains |
| 2019-11-13 | Baader Bank | Neutral | Initiate | |
| 2024-12-15 | H.C. WAINWRIGHT & CO., LLC | Buy | Buy | Maintains |
| 2024-08-29 | BAADER HELVEA EQUITY RESEARCH | Buy | Buy | Maintains |
| 2025-02-26 | H.C. WAINWRIGHT & CO., LLC | Buy | Buy | Maintains |
